
### [NCIT:C133592](http://purl.obolibrary.org/obo/NCIT_C133592)
**Label:** Recurrent Classical Hodgkin Lymphoma

**Subclasses:** [NCIT:C8649](http://purl.obolibrary.org/obo/NCIT_C8649) (Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma), [NCIT:C136971](http://purl.obolibrary.org/obo/NCIT_C136971) (Recurrent Lymphocyte-Rich Classical Hodgkin Lymphoma), [NCIT:C8832](http://purl.obolibrary.org/obo/NCIT_C8832) (Recurrent Mixed Cellularity Classical Hodgkin Lymphoma), 

**Class expressions from DL-Learner:**

- Thing 54.74%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) 36.78%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39956](http://purl.obolibrary.org/obo/NCIT_C39956) (Rete Testis Adenoma))) 36.78%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C3994](http://purl.obolibrary.org/obo/NCIT_C3994) (Stage IV Colon Cancer AJCC v6))) 36.78%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C3993](http://purl.obolibrary.org/obo/NCIT_C3993) (Stage II Colon Cancer AJCC v6))) 36.78%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39914](http://purl.obolibrary.org/obo/NCIT_C39914) (Gain of Chromosome 12p))) 36.78%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C3991](http://purl.obolibrary.org/obo/NCIT_C3991) (Thrombocytopenia Due to Immune Destruction))) 36.78%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39909](http://purl.obolibrary.org/obo/NCIT_C39909) (Gain of Chromosome 18q))) 36.78%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39907](http://purl.obolibrary.org/obo/NCIT_C39907) (Seminal Vesicle Cystadenoma))) 36.78%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39906](http://purl.obolibrary.org/obo/NCIT_C39906) (Seminal Vesicle Adenocarcinoma))) 36.78%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39905](http://purl.obolibrary.org/obo/NCIT_C39905) (Prostate Stromal Proliferation of Uncertain Malignant Potential))) 36.78%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39903](http://purl.obolibrary.org/obo/NCIT_C39903) (Prostate Adenocarcinoma with Focal Neuroendocrine Differentiation))) 36.78%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39902](http://purl.obolibrary.org/obo/NCIT_C39902) (Prostate Basal Cell Carcinoma))) 36.78%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39901](http://purl.obolibrary.org/obo/NCIT_C39901) (Prostatic Duct Urothelial Carcinoma))) 36.78%
- [NCIT:C32725](http://purl.obolibrary.org/obo/NCIT_C32725) (Hematopoietic and Lymphoid Cell) and (not ([NCIT:C39899](http://purl.obolibrary.org/obo/NCIT_C39899) (Secondary Prostate Urothelial Carcinoma))) 36.78%


